Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation.

OBJECTIVE In this 3 year randomized clinical trial the cost effectiveness of a 6 week educational/cognitive intervention (ECO) is compared with an educational discussion intervention (EDI) and a waiting list condition (WLC). METHODS A total of 131 patients with fibromyalgia were randomly allocated to the ECO, EDI, or WLC intervention. The ECO and EDI groups were followed for 12 months, whereas the WLC group was followed for 6 weeks. Direct health care and nonhealth care costs, and the indirect costs associated with lost production due to illness, were calculated. The effects were measured in terms of utilities, using rating scale and standard gamble methods. RESULTS Treatment costs were estimated to be US $980 per patient for both ECO and EDI. The total direct health care costs of ECO treatment were US $1623 higher than those for EDI. This difference was significant. Indirect costs for the 2 groups were not significantly different. At 6 weeks there was a significant difference in rating scale utilities between the 3 groups, caused by a significantly greater improvement in the EDI group compared to the WLC group. However, no significant differences in either rating scale or standard gamble utilities were found between the ECO and EDI groups immediately after treatment, or at the 6 or 12 month followups. CONCLUSION The economic evaluation showed that the addition of a cognitive component to the educational intervention led to significantly higher health care costs and no additional improvement in quality of life compared to the educational intervention alone. This conclusion is robust through a range of plausible values used in a sensitivity analysis.

[1]  J. Vlaeyen,et al.  Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. , 1996, The Journal of rheumatology.

[2]  Maureen,et al.  Methodological Issues of Patient Utility Measurement Experience From Two Clinical Trials , 1995, Medical care.

[3]  S. van der Linden,et al.  Patient utilities in ankylosing spondylitis and the association with other outcome measures. , 1994, The Journal of rheumatology.

[4]  A. Steere,et al.  Empirical Parenteral Antibiotic Treatment of Patients with Fibromyalgia and Fatigue and a Positive Serologic Result for Lyme Disease: A Cost-Effectiveness Analysis , 1993, Annals of Internal Medicine.

[5]  G. Girolamo Epidemiology and social costs of low back pain and fibromyalgia. , 1991 .

[6]  G. A. Mccain,et al.  The problem of longterm disability payments and litigation in primary fibromyalgia: the Canadian perspective. , 1989, The Journal of rheumatology. Supplement.

[7]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[8]  F. Wolfe,et al.  Fibromyalgia: the clinical syndrome. , 1989, Rheumatic diseases clinics of North America.

[9]  F. Wolfe,et al.  Pain, functional disability, and psychological status: a 12-month study of severity in fibromyalgia. , 1988, The Journal of rheumatology.

[10]  F. Wolfe,et al.  Socioeconomic impact of fibrositis. A study of 81 patients with primary fibrositis. , 1986, The American journal of medicine.